← Leaderboards
Emmanuel T Akporiaye
University Of Arizona
$2,801,106
Attributed
$2,801,106
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $400K · FY2005–21$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,801,106 · 5
By mechanism
R01$2,050,979 · 2
R43$750,127 · 2
P50$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Arizona
Same institution · by research overlap
- Karen Taraszka Hastings$848,385
- Tony L Yaksh$23,138,803
- Qing-Yu Zhang$3,459,764
- Daniel C Liebler$31,936,749
- Xinxin Ding$16,563,001
Others in their field
Top investigators on “Dendritic Cells”
- Barton F Haynes · Duke University$112,608,041
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- James C. Paulson · Scripps Research Institute$41,568,802
- Ulrich H Von Andrian · Harvard Medical School$32,521,007
- Donald L Morton · John Wayne Cancer Institute$29,042,629
Research focus
Dendritic CellsCytokineTumor GrowthCancer CellTumorToxic EffectMalignant NeoplasmsAdverse EffectsNeoplastic CellNeoplasm MetastasisPharmaceutical PreparationsPropertyTissuesT-LymphocyteImmunePrimary NeoplasmResponseApoptosisOralPre-ClinicalCellsAcidsChemotherapyImmunity
Grant awards (13)
Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA-Lys in Combination with Trastuzumab Against HER2/neu Positive Breast Cancer$399,999
R43 · FY2021 · CA · contact PI
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade$50,521
R43 · FY2019 · CA · contact PI
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade$299,607
R43 · FY2018 · CA · contact PI
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog$248,463
R01 · FY2010 · CA · contact PI
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog$241,727
R01 · FY2009 · CA · contact PI
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog$171,695
R01 · FY2008 · CA · contact PI
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog$86,515
R01 · FY2008 · CA · contact PI
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog$258,210
R01 · FY2007 · CA · contact PI
Effect of Tumor Derived TGF B on Dendritic Cell Vaccines$287,850
R01 · FY2005 · CA
Effect of Tumor Derived TGF B on Dendritic Cell Vaccines$244,673
R01 · FY2004 · CA
Effect of Tumor Derived TGF B on Dendritic Cell Vaccines$244,673
R01 · FY2003 · CA
Effect of Tumor Derived TGF B on Dendritic Cell Vaccines$267,173
R01 · FY2002 · CA
MUC1 - SPECIFIC IMMUNOTHERAPY OF COLON CANCER$0
P50 · FY2002 · CA